Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2016-06-01 Investor Presentation
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Wilson HTM Rapid Insights Conference Presentation 11 pages 1.2MB
Investor Presentation Classification · 95% confidence The document is a detailed investor conference presentation from Mayne Pharma Group Limited dated June 2, 2016. It includes company overview, financial highlights for the first half of 2016 (1H16), product pipeline, market share data, leadership team information, and strategic growth opportunities. The content is structured as a presentation with slides and charts, focusing on financials, strategy, and market position. There is no indication that this is a full annual or interim report, audit report, earnings release, or regulatory filing. The document is not a transcript of a call but rather a prepared presentation for investors. Therefore, the document best fits the category of an Investor Presentation (IP).
2016-06-01 English
Change in substantial holding from BTT 13 pages 295.0KB
Major Shareholding Notification Classification · 100% confidence The document is a Notice of Change of Interests of Substantial Holder filed under section 671B of the Corporations Act 2001 (Cth). It includes detailed information about changes in voting power and shareholdings of BT Investment Management Limited in Mayne Pharma Group Limited, including transaction history and relevant interests. The document is a formal regulatory filing notifying the market and the company of changes in substantial shareholdings, consistent with the definition of Major Shareholding Notification filings. It is not an annual report, earnings release, or any other financial report type, but a specific notification about share ownership changes.
2016-05-31 English
Mayne Pharma receives FDA approval for Doryx MPC tablets 2 pages 161.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 23 May 2016 from Mayne Pharma regarding FDA approval for a new drug formulation, Doryx MPC tablets. It contains no financial statements, no management discussion of financial results, no regulatory certifications, or voting results. It is a corporate announcement about a product approval and patent information. The document length is about 5,810 characters, which is relatively short and focused on a specific event. This fits best with a Regulatory Filings (RNS) category, which covers general regulatory announcements and miscellaneous filings that do not fit other categories. It is not an earnings release, annual report, or any other financial or governance report. Therefore, the classification is RNS with high confidence.
2016-05-22 English
Appendix 3B 9 pages 334.9KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B' and is an announcement related to a new issue of securities, application for quotation of additional securities, and agreement. It contains detailed information about the class of securities issued, number of securities, issue price, purpose of the issue, and other related details. The document references ASX (Australian Securities Exchange) rules and compliance, and it is structured as a formal announcement of securities issuance and quotation application. There is no indication of financial statements, management discussion, or audit information. The document is not a report but an announcement of a capital market transaction involving new share issuance and quotation application. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is not a mere brief announcement or report publication notice but a detailed capital issuance announcement.
2016-04-21 English
Appendix 3B and lapse of employee options 10 pages 902.4KB
Capital/Financing Update Classification · 95% confidence The document is a formal announcement addressed to the ASX Limited regarding employee share options that have lapsed and details about new securities issued, including ordinary shares and employee options. It includes an Appendix 3B form, which is a standard ASX form used for new issue announcements, applications for quotation of additional securities, and agreements related to securities issuance. The document contains detailed information about the securities issued, exercise prices, expiry dates, and the number of securities, which are typical for capital raising or share issuance disclosures. There is no financial performance data, management discussion, or audit information. The document is not a report but an announcement of securities issuance and related capital changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence level.
2016-04-04 English
Appendix 3B 9 pages 425.3KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B' and is an announcement related to the issuance of new securities, specifically the issuance of 500,000 ordinary shares by Mayne Pharma Group Limited. It includes detailed information about the class of securities, number issued, issue price, purpose of the issue (exercise of unlisted options), and compliance with ASX listing rules. The document also contains a quotation agreement for the securities to be listed on the ASX and details about employee options issued under an employee share option plan. There is no financial performance data, management discussion, or audit information. The document is a formal announcement of a capital change event (new share issue) rather than a report or financial statement. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is over 13,000 characters, indicating it is a full announcement, not a brief notice or report publication announcement.
2016-03-06 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.